Cargando…

Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach

Beta-lactam antibiotics are often the backbone of treatment for Gram-negative infections in the critically ill. Beta-lactams exhibit time-dependent killing, and their efficacy depends on the percentage of dosing interval that the concentration remains above the minimum inhibitory concentration. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maguigan, Kelly L., Al-Shaer, Mohammad H., Peloquin, Charles A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532626/ https://www.ncbi.nlm.nih.gov/pubmed/34680734 http://dx.doi.org/10.3390/antibiotics10101154

Ejemplares similares

Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections
por: Gatti, Milo, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients
por: Han, Ruiying, et al.
Publicado: (2021)

1101. Implementing a Beta-Lactam Therapeutic Drug Monitoring Program: Experience from a Large Academic Medical Center
por: Veena, Venugopalan, et al.
Publicado: (2021)

Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives
por: Garcia-Bustos, Víctor, et al.
Publicado: (2022)

Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?
por: Bassetti, Matteo, et al.
Publicado: (2016)

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians
por: Principe, Luigi, et al.
Publicado: (2022)

Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy
por: FakhriRavari, Alireza, et al.
Publicado: (2022)

Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy
por: Ulldemolins, Marta, et al.
Publicado: (2014)

Beta-lactam antibiotics in continuous infusion in critically ill patients
por: Jeurissen, Axel, et al.
Publicado: (2010)

Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis
por: Wang, Chuhui, et al.
Publicado: (2021)

Continuous beta-lactam infusion in critically ill patients: the clinical evidence
por: Abdul-Aziz, Mohd H, et al.
Publicado: (2012)

976. Population Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analysis of Intravenous Fosfomycin for Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

1825. Optimizing β-lactam Therapy in Surgical Intensive Care Unit Patients Using Therapeutic Drug Monitoring
por: Al-Shaer, Mohammad H, et al.
Publicado: (2019)

Effects of reducing beta-lactam antibiotic pressure on intestinal colonization of antibiotic-resistant gram-negative bacteria
por: Nijssen, Saskia, et al.
Publicado: (2009)

Clinical Relevance of Antibiotic Susceptibility Profiles for Screening Gram-negative Microorganisms Resistant to Beta-Lactam Antibiotics
por: Montiel-Riquelme, Francisco, et al.
Publicado: (2020)

Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients
por: Heil, Emily, et al.
Publicado: (2017)

Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia
por: Tran, Nikki N, et al.
Publicado: (2023)

Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review
por: Venuti, Francesco, et al.
Publicado: (2023)

Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?
por: Van Herendael, Bruno, et al.
Publicado: (2012)

Development of a Predictive Dosing Nomogram to Achieve PK/PD Targets of Amikacin Initial Dose in Critically Ill Patients: A Non-Parametric Approach
por: Coste, Anne, et al.
Publicado: (2023)

Some Suggestions from PK/PD Principles to Contain Resistance in the Clinical Setting—Focus on ICU Patients and Gram-Negative Strains
por: Adembri, Chiara, et al.
Publicado: (2020)

Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial
por: Ewoldt, Tim M. J., et al.
Publicado: (2022)

Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections
por: Gatti, Milo, et al.
Publicado: (2023)

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
por: Barbier, François, et al.
Publicado: (2023)

Correction to: Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia
Publicado: (2023)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
por: Veiga, Rui Pedro, et al.
Publicado: (2018)

The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients
por: Novy, Emmanuel, et al.
Publicado: (2023)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

β-lactam precision dosing in critically ill children: Current state and knowledge gaps
por: Tang Girdwood, Sonya, et al.
Publicado: (2022)

PD32 - Non-immediate type beta-lactam allergy in childhood
por: Cavkaytar, Ozlem, et al.
Publicado: (2014)

Beta-lactam antibiotic test doses in the emergency department
por: Maguire, Michelle, et al.
Publicado: (2020)

2953. PK/PD Comparison of a New Dosing Scheme for Meropenem Adapted to Outpatient Parenteral Antimicrobial Therapy (OPAT) in Non-Critically-Ill Patients
por: Briquet, Caroline, et al.
Publicado: (2023)

Mechanical penetration of β-lactam–resistant Gram-negative bacteria by programmable nanowires
por: Liu, Lizhi, et al.
Publicado: (2020)

Enhancement of β-Lactam-Mediated Killing of Gram-Negative Bacteria by Lysine Hydrochloride
por: Hong, Shouqiang, et al.
Publicado: (2023)

Identifying “at-risk” patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections
por: Abdul-Aziz, Mohd H., et al.
Publicado: (2017)

Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?
por: Barreto, Erin F., et al.
Publicado: (2021)

Update on Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Critically Ill Patients—A Narrative Review
por: Stašek, Jan, et al.
Publicado: (2023)

Gram-negative bacteremia is an independent predisposing factor for critical illness polyneuromyopathy
por: Kritikos, K, et al.
Publicado: (2007)

Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either gram negative or gram positive bacteria
por: Charles, Pierre Emmanuel, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_qe3ltf08f8f4cvu7f6nv4pqju7